Affiliation:
1. Soochow University
2. The First Affiliated Hospital of Soochow University
Abstract
Abstract
B/T mixed phenotype acute leukemia (MPAL), which represents only 2-3% of all MPAL cases, is classified as a high-risk leukemia subtype. Adults diagnosed with B/T MPAL have a notably low three-year survival rate, estimated at 20–40%. The rarity and undercharacterization of B/T MPAL present substantial challenges in identifying an optimal treatment protocol. This report aims to shed light on this issue by presenting a case in which a patient with a complex karyotype was treated using a combination of Venetoclax, Azacitidine, and Blinatumomab. This novel, chemo-free regimen resulted in the patient achieving both hematologic and molecular complete remission , with no severe organ or hematological toxicity observed. Notably, the patient continued to maintain molecular remission for 1 years following the transplantation. Based on these findings, the combination of Venetoclax, Azacitidine, and Blinatumomab could be considered a potential therapeutic approach for B/T MPAL patients, meriting further investigation.
Publisher
Research Square Platform LLC
Reference22 articles.
1. Matutes E, Winfried F, Pickl, Mars, van't Veer et al (2011) Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. ; 117 (11): 3163–3171
2. Mixed-phenotype acute leukemia: historical overview and a new definition;Weinberg OK;Leukemia,2010
3. Acute leukemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations;Gerr H;Br J Haematol,2010
4. The genetic basis and cell of origin of mixed phenotype acute leukemia;Alexander TB;Nature,2018
5. Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital;Rubnitz JE;Blood,2009